Oventus Medical (ASX:OVN) Clinical Director Dr Chris Hart presents at the ASX CEO Session in Sydney
Oventus Medical (ASX:OVN) Clinical Director Dr Chris Hart presents at the ASX CEO Session in Sydney, 15 November 2016
Oventus Medical is an Australian medical device company. We have a proprietary oral appliance and we are working in the area of sleep-disordered breathing from snoring to obstructive sleep apnoea.
We aim to become a global leader in OSA with an initial focus on patients who aren’t being efficiently treated at the moment. We’ve found that with our O2 Vent device we can treat patients with nasal obstruction as well as those without it, and that has not been shown in peer reviewed data.
We think that we are more effective than other oral appliances and there are further studies under way to confirm that. We are about 75 to 80 per cent as effective as CPAP but it is worn nearly twice as much. Our average wearing time is 7 hours a night, compared to 3.3 hours for CPAP, so the impact on disease is actually higher than CPAP.
To view this presentation and to read the full transcript, click the image below.